Supplementary Figures 1 through 3 from RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression

The supplemental file contains three supplemental figures (Figures S1-S3), their figure legends and additional methods not included in the manuscript. Figure S1 shows hematoxylin and eosin (H&E) staining of tumor free skin and melanomas from mice of all genotypes to demonstrate that the MDM2C305F mutation does not affect the pathophysiology of oncogenic RAS overexpression-induced tumorigenesis. Figure S2 is complementary to Figure 2 in the manuscript. It provides mRNA and protein expression of RPL23 and RPL11 in additional genotypes of mouse and MEFs. We tested RPL23 and RPL11 expression in response to RAS overexpression and MDM2C305F mutation. Additionally, Figures S2G-H show the raw data that is summarized in Figure 2J, and Figure S2I shows a summary of RPL11 half-life from the raw data in Figure S2G-H. This figure supports the notion that RPL23 mRNA and protein levels increase in response to RAS and MDM2C305F mutation and show that protein stability is unchanged in Mdm2m/m MEFs. Figure S3 is complementary to Figure 3 in the manuscript. These data show that the upregulation of RPL23 in response to RAS is conserved in a human cell line (HEK-293).